On the one hand, overseas medical services have entered China, and on the other hand, China's medical capital has been intensively exported. Around 2016, overseas medical investment has entered a period of full-scale outbreak.
SMI Swiss Medical Investment International Group (hereinafter referred to as "SMI"), which entered China eight years ago, decided to officially launch its overseas investment business, "taking Chinese investors to negotiate investment abroad."
To this end, at the end of July, SMI teamed up with the Guangzhou Daily Guangdong Chamber of Commerce, Biodata Medical Investment Forum, and the Geneva Global Doctors Association to launch the Biodata Guangdong Business Dual Engine Program, which includes two face-to-face global medical doctors and Biodata Medical Investment Club, focusing on health and capital. .
SMI's executive director in China, Lin Gang, told the 21st Century Business Herald: "The reason for the change from Chinese and foreign exchanges to capital cooperation is mainly related to changes in the international economy and investment environment. Previously, overseas projects have reserved for Chinese investors, now Overseas medical institutions are increasingly willing to share their mature projects and profit models with domestic investors."
In addition to SMI, the 21st Century Business Herald reporter understands that, following the entrepreneurial group's search for overseas e-commerce resources in the past few days, the current group's search for overseas medical and pharmaceutical standards is in full swing.
Looking at the first half of this year, the main force of overseas medical investment mergers and acquisitions is listed companies. According to statistics, the acquisition of overseas pharmaceutical, biotechnology and medical assets by domestic companies has exceeded 3.9 billion US dollars, which exceeds the total investment in 2015, which is ten times that of 2012.
According to Zhao Wei, CEO of the pottery network, after several years of development, the price of domestic medical targets has been very high, while the standards of models and technological innovations are few. In contrast, overseas investment opportunities are high and risks are low. At present, China's capital is mainly focused on new drugs, medical devices and other fields. Post-investment management and localization will be a major challenge.
High-end medical care in the Chinese market
According to the 21st Century Business Herald reporter, SMI will integrate world famous doctors through “global doctors face to face†to launch health knowledge lectures and cutting-edge technology and expert exchange activities for Cantonese businessmen. The Biodata Investment Club provides investors with a platform for communication and information transfer with foreign medical companies through online and offline activities, and helps solve financing difficulties in the investment process.
In the second half of this year, the club will organize medical exchange summits, medical investment forums and other activities, and organized a delegation to overseas field visits.
“We started this plan last year. We have been in China for 8 years and have been in the communication observation stage before.†As a liaison representative of SMI’s Chinese and foreign businesses, Lin Gang recalls, “Now, overseas institutions feel that the Chinese market has grown and Europe The economic situation is not as good as before. In the past three years, many local governments have stopped funding some medical projects, so they rely on the Chinese market and capital to promote the development of the project in China. Some institutions even hope that Chinese investors will invest in the European parent company. Compared to the past, attitudes have changed a lot."
SMI, formerly known as the Geneva Medical Association of Switzerland, was founded in 2001 in Geneva, Switzerland. Entrusted by the Swiss government, SMI founded the BIODATA International Medical Investment Forum in 2002 and held the International Medical Expo for 11 consecutive years.
Since last year, SMI has gradually accelerated its docking with Chinese capital, including co-sponsoring the BioData Medical Investment Club with the Guangzhou Daily Guangdong Chamber of Commerce. In March of this year, Hainan Provincial Cancer Hospital Chengmei International Medical Center invested by Hainan No. 1 Investment Holding Group was established, and SMI participated as a technology and service provider.
At the same time, SMI's Swiss-owned private medical center is also opened in Guangzhou, which locates the high-end medical market and provides a global “full-stage, uninterrupted†private medical service for white-collar elites in China. Elvir Cograin, chairman and president of SMI's board of directors and sponsor of the BioData Forum, revealed that in the future, two to five high-end private hospitals, 100 private medical centers, and 10,000 family doctors will be established in China.
Automatic Fire Alarm Control Panels And Fire Display Panel
Fire Control Panel,Fire Alarm Control Panel,Intelligent Fire Alarm Control Panel,Linkage Control Panel
LIAONING YINGKOU TIANCHENG FIRE PROTECTION EQUIPMENT CO.,LTD , https://www.tcfiretech.com